All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

Agilent's PD-L1 diagnostic wins FDA approval alongside Merck & Co.'s Keytruda for ovarian cancer patient identification
Antibody, cancer, monoclonal antibody, ovarian cancer, PD-L1 target, companion diagnostic - Read more

FDA approves Novocure's Optune Pax wearable device for locally advanced pancreatic cancer treatment
Device therapy, cancer, tumor treating fields, pancreatic cancer, combination therapy - Read more

THE GOOD
Business Development & Partnerships

Nxera Pharma, Centessa Pharmaceuticals milestone triggers $1.8M payment for orexin receptor agonist ORX489
Research collaboration, neurological, small molecule, milestone payments - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Lundbeck's bocunebart (PACAP-targeting antibody) meets Ph2 primary endpoint for migraine prevention in treatment-resistant patients
Monoclonal antibody, neurological, migraine prevention, PACAP target, treatment-resistant patients - Read more

BridgeBio Pharma's infigratinib FGFR3 inhibitor shows impressive Ph3 results in achondroplasia, enabling regulatory filing
Small molecule, rare disease, FGFR3 inhibitor, achondroplasia, pediatric population - Read more

THE GOOD
Company Incubation

European Life Sciences Coalition launches in Brussels to strengthen Europe's biotechnology venture capital investment ecosystem
Investment ecosystem, strategic, financial, venture capital - Read more

THE GOOD
Earnings & Finances

Alnylam Pharmaceuticals achieves first-ever profitability with $314M net income despite disappointing Amvuttra Q4 revenue
RNAi therapeutics, cardiovascular, financial, profitability milestone - Read more

THE GOOD
Fundraises

LEON raises undisclosed financing for global LNP manufacturing scale-up systems
Platform technology, CDMO, manufacturing, RNA therapeutics - Read more

OKYO Pharma raises $20M public offering, developing therapies for neuropathic corneal pain
Ophthalmology, clinical-stage, neuropathic pain, inflammatory diseases - Read more

Evommune announces $125M private placement, advancing clinical programs for inflammatory diseases
Clinical-stage, autoimmune, chronic inflammatory diseases - Read more

Coherus Oncology raises $50.1M public offering, commercializing LOQTORZI and clinical development
Oncology, antibody, clinical-stage, commercialization - Read more

THE GOOD
Investments

Novo Nordisk plans Ireland facility expansion to produce Wegovy pill for overseas markets beyond US
Small molecule, obesity, strategic, investment - Read more

CARsgen Therapeutics signs agreements for RMB370M CAR-T manufacturing base expansion in Shanghai's Jinshan District
CAR-T, oncology, strategic, major transaction, operational - Read more

THE GOOD
Lawsuits

Astellas settles Myrbetriq patent litigation with Lupin and Zydus for $210 million combined upfront payments
Small molecule, urological, strategic, major transaction, patent settlement - Read more

Samsung Bioepis, Regeneron settle Eylea biosimilar patent dispute, enabling US launch January 2027
Licensing deal, ophthalmology, biosimilar, antibody - Read more

THE GOOD
Market Reports

Novo Nordisk's oral Wegovy attracts 36% new GLP-1 patients since December approval, expanding market access
GLP-1 agonist, obesity, strategic, market expansion - Read more

THE GOOD
Product Launches

Terray Therapeutics debuts EMMI Predict:TerraBind AI model with 20% better accuracy than leading competitors
Small molecule, AI drug discovery, operational, competitive - Read more

THE GOOD
Regulatory

FDA removes boxed warnings from six menopausal hormone therapy products after comprehensive scientific review
Hormone therapy, women's health, regulatory, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Earnings & Finances

CSL replaces CEO after net profit plummets from $2B to $384M amid restructuring costs
Iron replacement therapy, kidney disease, financial, operational, strategic - Read more

THE BAD
Lawsuits

AbbVie sues HHS and CMS alleging Botox wrongly included in drug price negotiation program as plasma-derived product
Botulinum toxin, neurological, regulatory, pricing pressure - Read more

THE BAD
Layoffs

Seres Therapeutics lays off 30% workforce, pauses SER-155 phase 2 trial amid funding constraints
Microbiome therapy, infectious disease, operational, cost reduction - Read more

THE BAD
Regulatory

PTC Therapeutics withdraws FDA application for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy
Protein therapy, neurological, nonsense mutation Duchenne muscular dystrophy, protein restoration therapy, ataluren - Read mode

THE UGLY
Earnings & Finances

Icon shares plummet 37% after CRO launches accounting investigation, withdraws 2025 guidance over revenue overestimates
CRO services, financial, operational, major transaction - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here